Artículos

Artículo

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study

Carmine Valenza, MD, MPH; Yue Zheng, MSc; Monica Milano, MD, PhD; Dario Trapani, MD; Elisa Giordano, MD; Lorenzo Guidi, MD; Pier Paolo Maria Berton Giachetti, MD; Laura Boldrini, MD; Grazia Castellano, MD; Jalissa Katrini, MD; Bianca Malagutti, MD; Gabriele Antonarelli, MD, PhD; Fabio Conforti, MD, PhD; Eleonora Pagan, PhD; Vincenzo Bagnardi, PhD; Gregory J. Kirkner, MPH; Claudia Sangalli, BSc; Kate E. Dibble, PhD; Marco Colleoni, MD; Meredith M. Regan, ScD; Elisabetta Munzone, MD; Giuseppe Curigliano, MD, PhD; and Ann H. Partridge, MD, MPH

Artículo 5 de noviembre de 2026 NuPe Módulo 3

To evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with node-positive, hormone receptor–positive early breast cancer (eBC).

Artículo

Prescribing Patterns and Real-World Clinical Usage of Adjuvant Abemaciclib for Early-Stage, High-Risk, Estrogen Receptor-Positive Breast Cancer

Sneha Rajendran, MD; Alexander Chih-Chieh Chang, BS; Valerie Gao, MD; Faith Seltun, DO; Zhexi Lu, MD; David Lazris, MD; Joshua Wang, BS; Kathryn Demanelis, PhD; and Julia Foldi, MD, PhD

Artículo 5 de noviembre de 2026 NuPe Módulo 3

Based on improved invasive disease-free survival in the monarchE trial, the US Food and Drug Administration (FDA) approved abemaciclib for adjuvant treatment of high-risk, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)–negative breast cancer…

Artículo

Multimodal De-Escalation Strategies in Early Breast Cancer

Icro Meattini, MD; Ana Tecic Vuger, MD, PhD; Carlotta Becherini, MD; Eliza J. Epstein, BA; John P. Garcia, MD; Elizabeth R. Berger, MD, MS; and Nadia Harbeck, MD, PhD

Artículo 5 de noviembre de 2026 NuPe Módulo 2

The excellent cure rates documented in clinical trials today constitute a very high bar for attempts to de-escalate therapy for early-stage breast cancer (EBC). Moreover, any therapy de-escalation must be made in the context of an optimal multimodal treatment concept as…

Artículo

Navigating Treatment Decisions in Early-Stage Hormone Receptor–Positive Breast Cancer

Eitan Amir, MB, PhD; Tyler Kristoff, MD; Catherine Blaha, MD, PhD; Uri Bender, MSc, MDCM; Kevin Kalinsky, MD, MS, FASCO; and Erin Cobain, MD

Artículo 5 de noviembre de 2026 NuPe Módulo 2

Treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is increasingly complex, driven by a growing array of therapeutic options, heterogeneous clinical benefit across patient subgroups, and the risk of…

Artículo

Artificial Intelligence in Oncology: Clinical Applications, Challenges, and Opportunities

Gerneiva Parkinson, MD, MHS; Rima Patel, MD; Colin Bergstrom, MD; Brian Vadasz, MD; Mohamed Amgad, MD; Lee A.D. Cooper, PhD; Joseph Sparano, MD; and Janice Lu, MD, PhD

Artículo 5 de noviembre de 2026 NuPe Módulo 1

Artificial intelligence (AI) is reshaping cancer research and clinical oncology by enabling large-scale analysis of complex biomedical data. Although early AI efforts focused on single-modality tasks such as imaging interpretation or pathology classification, contemporary…

Artículo

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights

Ko Un Park, MD; Raymond B. Mailhot Vega, MD, MPH; Samantha Shams, MD; Jeffrey Hawley, MD; Mark R. Somerfield, PhD; Alastair M. Thompson, MD, MBChB; and Mylin A. Torres, MD

Artículo 5 de noviembre de 2026 NuPe Módulo 1

Artículo

Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries

Regina Barragan-Carrillo, MD; Fredrick Chite Asirwa, MD; Rodrigo Dienstmann, MD, MBA; Dinesh Pendhakar, MD, PhD; y Erika Ruiz-Garcia, MD, MS

Artículo 5 de noviembre de 2026 NuPe Módulo 1